Hansoh Pharmaceutical (03692.HK) Rises Over 3% as Core Innovation Capabilities Gain Validation; Poised for Catalyst Wave in Next Two Years

According to the Zhishang Finance APP, Hansoh Pharma (03692) rose over 3%. As of the time of writing, it was up 3.48%, trading at HK$17.26, with a turnover of HK$8.0153 million.

Huatai Securities released a research report pointing out that Hansoh Pharma is one of the more successful comprehensive pharmaceutical companies in China in terms of innovation transformation. It has a total of 8 marketed innovative drugs, ranking second among pharmaceutical companies in China. The approval progress of these 8 marketed innovative drugs ranks among the top two in their respective categories in China. Moreover, they have advantages over competing products in terms of efficacy and safety. The underlying innovative strength has been gradually verified, and the next two years may witness a wave of innovative catalysts.

The bank pointed out that it is optimistic about the realization of the company's global innovative transformation: 1) The revenue share of innovative drugs in 1H24 has broken through 70% and is showing an increasing trend; 2) The company is expected to usher in a wave of new product approvals in 2025/26; 3) The international competitiveness of the pipeline is evident, with three high-value BD varieties provided to MNCs; judging from the progress of the pipeline, the trend of new drug exports is expected to take shape.